Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 1331 results for heart OR cardi* OR arrythmia

  1. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

  2. Haematological cancers (QS150)

    This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (children, adults and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

  3. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  4. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

  5. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.

  6. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  7. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

  8. Adalimumab for treating moderate to severe plaque psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

  9. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  10. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  11. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  12. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.

  13. Interventions: What is the most clinically and cost‑effective management strategy for adults with calcific mitral stenosis and an indication for intervention?

    applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number

  14. Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes?

    applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number